Hot off the Forge
-
Declaration allows Forge to better support clients intending to export gene therapy products for clinical programs in Europe.
-
“We are encouraged by the continued safety and efficacy observed in FBX-101 treated patients. Notably, some of the patients were…
-
“Expanding our leadership team with these strategic hires… supports our vision for growth and the value we provide to our…
-
PRIME designation is granted to drug candidates that may offer a major therapeutic advantage over existing treatments, or benefit patients…
-
Forge will provide services to support Oculogenex’ gene therapy program for patients with dry age-related macular degeneration (AMD) toward clinical…
-
Among other updates, Forge to discuss adding plasmid DNA manufacturing to suite of gene therapy offerings.
-
Partnership will advance Eikonoklastes’ AAV-based gene therapy, ET-101, into clinical trials for the treatment of patients with amyotrophic lateral sclerosis…
-
The data from treated subjects demonstrate that intravenous FBX-101 after HSCT infusion has been safe and well tolerated.
-
Building on an AAV manufacturing partnership with new plasmid production, Forge’s end-to-end manufacturing services will help to advance Ray’ gene…
-
The partnership will help advance Myrtelle’s novel gene therapy for monogenic hearing loss, Myr-201, into clinical trials for patients with…
-
Conferences include upcoming Jefferies, Chardan, and SVB Securities healthcare conferences.
-
New offering complements Forge’s existing AAV process development, analytical development, cGMP manufacturing, and automated final fill capabilities.